IMC-2032

IMC-2032 is a preclinical-stage therapeutic candidate being developed by ImmuneCyte Life Sciences. It is built upon the company's proprietary **ProSTEM platform**, which focuses on stem cell-based interventions. The IMC-2032 program is currently being explored for two distinct indications: **beta-thalassemia**, where it is characterized as a cell-based gene therapy, and **Cockayne Syndrome** (a rare genetic disorder associated with premature aging), where it is developed as a stem cell therapy. The ProSTEM platform aims to utilize engineered stem cells to address underlying genetic or cellular deficiencies. As of the latest pipeline updates, both the beta-thalassemia and Cockayne Syndrome programs are in the preclinical or pilot phase of development.

Other names

beta-Thalassemia programCockayne Syndrome program